6-Cyclopropyl-6-fluorocyclohexa-2,4-diene-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 6-Cyclopropyl-6-fluorocyclohexa-2,4-diene-1-carboxylic acid
• 英文别名: 6-cyclopropyl-6-fluorocyclohexa-2,4-diene-1-carboxylic acid
• 化学式: C₁₀H₁₁FO₂
• 分子量: 182.19
• InChiKey: OLYLZYCYXSWKOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] LABELED AMINO PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINOPYRIMIDINE MARQUÉS
  申请人：NOVARTIS AG

  公开号：WO2016079669A1

  公开（公告）日：2016-05-26

  The present invention describes novel radioactive amino pyrimidine derivatives, their preparation and their use as radiotracers / radiomarkers for imaging techniques and as diagnostic tools in the field of BTK receptor susceptible diseases and/or disorders. The compounds of the present invention generally exhibit a potent and selective inhibition of Bruton's tyrosine kinase (BTK).

  本发明描述了新型放射性氨基嘧啶衍生物，它们的制备以及它们作为影像技术中的放射示踪剂/标记物以及在BTK受体易感性疾病和/或疾病领域中作为诊断工具的用途。本发明的化合物通常表现出对布氏酪氨酸激酶（BTK）的强效和选择性抑制。
• N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN
  申请人：Genentech, Inc.

  公开号：EP2855428A1

  公开（公告）日：2015-04-08
• SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
  申请人：GENENTECH, INC.

  公开号：EP3297989A1

  公开（公告）日：2018-03-28
• [EN] N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN<br/>[FR] BENZAMIDES N-SUBSTITUÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE LA DOULEUR
  申请人：GENENTECH INC

  公开号：WO2013177224A1

  公开（公告）日：2013-11-28

  The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
• [EN] SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF<br/>[FR] BENZAMIDES SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2016191312A1

  公开（公告）日：2016-12-01

  The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.